MacroGenics Announces Pricing of Public Offering of Common Stock
Mar 28, 2018 11:30 am UTC| Business
ROCKVILLE, MD, March 28, 2018 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment...
Mar 28, 2018 11:30 am UTC| Business
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting NaPi2b Appointed David...
Mar 28, 2018 11:30 am UTC| Business
NEW YORK, March 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Meridian Bancorp,...
Mar 28, 2018 11:27 am UTC| Business
NEW YORK, March 28, 2018 -- Global Sinusitis Treatment Market size is expected to reach USD 50.41 Billion in 2024, at a CAGR of 12.4% from 2018 to 2024. Factors propelling the growth of the market include growing number...
Mar 28, 2018 11:20 am UTC| Business
SAN JUAN, Puerto Rico, March 28, 2018 -- Green Spirit Industries Inc. (OTC Pink:GSRX) (“Green Spirit” or, the “Company”) announced today that it has been issued the requisite establishment license by the Department of...
ArcelorMittal announces the completion of its share buyback program
Mar 28, 2018 11:07 am UTC| Business
Luxembourg, 28 March 2018 - ArcelorMittal announces the completion of its share buyback program on 26 March 2018. ArcelorMittal has repurchased 7 million shares for a total value of approximately €184,345,983 (equivalent...
Mar 28, 2018 11:05 am UTC| Business
HALIFAX, Nova Scotia, March 28, 2018 -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2 Study combining...